Hsa_circ_0006988 Promotes Sorafenib Resistance of Hepatocellular Carcinoma by Modulating IGF1 Using miR-15a-5p

• Published in: Canadian Journal of Gastroenterology and Hepatology Vol. 2022; pp. 1206134 - 8
• Main Authors: Qiu, Rui, Zeng, Zhifeng
• Format: Journal Article
• Language: English; French
• Published: Egypt Hindawi 2022; Hindawi Limited
• Subjects: Angiogenesis; Carcinoma, Hepatocellular - drug therapy; Carcinoma, Hepatocellular - genetics; Gene expression; Humans; Incorporation; Insulin-Like Growth Factor I - genetics; Liver cancer; Liver Neoplasms - drug therapy; Liver Neoplasms - genetics; MicroRNAs; MicroRNAs - genetics; RNA, Circular - genetics; Sorafenib - pharmacology; Targeted cancer therapy; Variance analysis; United States > US; China

Background. Hepatocellular carcinoma (HCC) is the most frequently occurring cancer and contributes to the largest number of cancer-associated deaths worldwide. Recent evidence suggests that circular RNAs (circRNAs), which are critical for HCC etiology and metastasis, are distinctly modulated in HCC....